Naltrexone Treatment Centers in Wisconsin

Yes. Federal guidance and Wisconsin law protect your right to continue FDA-approved MAT while under community supervision. Share your probation-officer contact with the clinic so they can document treatment — probation cannot legally require you to stop naltrexone.

Many Wisconsin community behavioral-health agencies and federally qualified health centers offer sliding-scale fees based on household income. Sliding-scale fees commonly bring a weekly methadone visit down to $5–$25. Ask naltrexone providers in your area about discounted rates when you call.

Usually yes, if your provider is in-network with the new plan. Wisconsin MAT clinics typically contract with all major BadgerCare Plus managed-care organizations. Verify the provider’s network status before the effective date of your new plan to avoid interruption.

Yes. Medicare Part B covers methadone through enrolled Opioid Treatment Programs and Part D covers buprenorphine and naltrexone prescriptions. Medicare Advantage plans in Wisconsin include the same MAT benefits under the integrated plan structure.

Opioid Treatment Programs dispensing methadone must meet 42 CFR Part 8 standards for admission, dosing, counseling, and take-home criteria. Buprenorphine prescribing follows DEA Schedule III rules for controlled substances, and naltrexone has no scheduling requirement. SAMHSA and Wisconsin licensing agencies conduct periodic inspections at all MAT sites.

Yes. Returning to naltrexone after a gap in care is common and safe; your Wisconsin clinic will re-induct using the same protocols as first-time patients. The federal 1-year waiting period sometimes referenced for methadone does not apply to re-admission.

Go to the nearest emergency department; Wisconsin hospitals are equipped to initiate buprenorphine and connect you to outpatient MAT. You can also call 988 for a live counselor to locate an open bridge clinic or mobile MAT unit.

First doses are intentionally cautious — 5–10 mg of buprenorphine or 20–30 mg of methadone — to assess tolerance and avoid over-sedation. Your dose is titrated up over the first 1–2 weeks until cravings and withdrawal are controlled.

Methadone can prolong the QTc interval on ECG; Wisconsin clinics screen patients with baseline and follow-up ECGs. Buprenorphine and naltrexone do not carry this risk. Patients with cardiac disease can safely use MAT under close cardiology and MAT-team coordination.

Neonatal Opioid Withdrawal Syndrome (NOWS) can occur in infants exposed to methadone or buprenorphine prenatally and is routinely monitored at Wisconsin delivery hospitals. NOWS is manageable with skilled nursing care; most infants go home within days to weeks with normal outcomes.

Yes — counseling records are protected by 42 CFR Part 2 and HIPAA. The counselor cannot disclose your MAT status or session content to family, employer, or law enforcement without your specific written consent or a narrowly tailored court order.

Yes. Group members sign confidentiality agreements, and the clinician protects group content under 42 CFR Part 2. Enforcement between group members depends on honor among peers, but legal protections limit disclosure by the clinic or clinician.